Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership
18 Giugno 2020 - 7:19AM
Saint-Herblain, France, June 18, 2020 –
Valneva SE, (“Valneva”), a specialty vaccine company, and Bavarian
Nordic A/S (OMX: BAVA) today announced that they have signed a
binding term sheet to establish a partnership for the marketing and
distribution of their commercial products. The partnership will
provide both companies with additional critical mass, significant
commercial synergies and a market leadership position in the
specialty vaccine industry.
Under the agreed terms, Valneva will
commercialize Bavarian Nordic’s marketed vaccines leveraging its
commercial infrastructure in Canada, UK, France and Austria.
Valneva will also take responsibility for Belgium and the
Netherlands where it will set up new commercial operations.
Bavarian Nordic will commercialize Valneva’s marketed products in
Germany and Switzerland. The partnership includes vaccines that
protect against rabies, Japanese Encephalitis, tick-borne
encephalitis and cholera.
The agreement follows Bavarian Nordic’s recent
acquisition of two commercial vaccines from GlaxoSmithKline. The
transition from current arrangements will commence later this year
and through 2021 in line with existing distribution agreements.
Valneva expects limited additional revenues in 2020 with more
material impact from 2021 onwards.
Thomas Lingelbach, CEO of Valneva,
commented, “We are excited to join forces with Bavarian Nordic
to continue to build our commercial business and to enhance our
product offering to our customers. This partnership provides
excellent synergy for both companies as well as greater breadth in
our commercial portfolios.” Paul Chaplin, President
& CEO of Bavarian Nordic, added, “We are pleased to
collaborate with Valneva in the ongoing commercialization of our
business. Valneva’s strong commercial presence combined with our
accelerated establishment of a commercial infrastructure allows us
to implement the right go-to-market strategy in the different
markets and will provide mutual benefits by adding complementary
products to both companies’ portfolios.”
About Valneva SEValneva is a specialty
vaccine company focused on prevention against diseases with major
unmet needs. Valneva’s portfolio includes two commercial vaccines
for travelers: IXIARO®/JESPECT® indicated for the prevention of
Japanese encephalitis and DUKORAL® indicated for the prevention of
cholera and, in some countries, prevention of diarrhea caused by
ETEC. The Company has various vaccines in development including
unique vaccines against Lyme disease and chikungunya. Valneva has
operations in Austria, Sweden, the United Kingdom, France, Canada
and the US with over 500 employees. For more information,
visit www.valneva.com and follow the Company on LinkedIn.
About Bavarian NordicBavarian
Nordic is a fully integrated biotechnology company focused on the
development, manufacture and commercialization of life-saving
vaccines. Bavarian Nordic is a global leader in smallpox vaccines
and has been a long-term supplier to the U.S. Strategic National
Stockpile of a non-replicating smallpox vaccine, which has been
approved by the FDA under the trade name JYNNEOS®, also for the
protection against monkeypox. The vaccine is approved as a smallpox
vaccine in Europe under the trade name IMVANEX® and in Canada under
the trade name IMVAMUNE®. Bavarian Nordic’s commercial product
portfolio furthermore contains market-leading vaccines
Rabipur®/RabAvert® against rabies and Encepur® against tick-borne
encephalitis. Using its live virus vaccine platform technology,
MVA-BN®, Bavarian Nordic has created a diverse portfolio of
proprietary and partnered product candidates designed to save and
improve lives by unlocking the power of the immune system,
including an investigational Ebola vaccine, licensed to Janssen.
For more information visit www.bavarian-nordic.com.
Valneva Investor and Media ContactLaetitia
Bachelot-FontaineDirector Investor Relations & Corporate
CommunicationsM +33 (0)6 4516 7099
investors@valneva.com
Forward-Looking StatementsThis press
release contains certain forward-looking statements relating to the
business of Valneva, including with respect to the progress, timing
and completion of research, development and clinical trials for
product candidates, the ability to manufacture, market,
commercialize and achieve market acceptance for product candidates,
the ability to protect intellectual property and operate the
business without infringing on the intellectual property rights of
others, estimates for future performance and estimates regarding
anticipated operating losses, future revenues, capital requirements
and needs for additional financing. In addition, even if the actual
results or development of Valneva are consistent with the
forward-looking statements contained in this press release, those
results or developments of Valneva may not be indicative of future
performance. In some cases, you can identify forward-looking
statements by words such as "could," "should," "may," "expects,"
"anticipates," "believes," "intends," "estimates," "aims,"
"targets," or similar words. These forward-looking statements are
based largely on the current expectations of Valneva as of the date
of this press release and are subject to a number of known and
unknown risks and uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from any future results, performance or achievement
expressed or implied by these forward-looking statements. In
particular, the expectations of Valneva could be affected by, among
other things, uncertainties involved in the development and
manufacture of vaccines, unexpected clinical trial results,
unexpected regulatory actions or delays, competition in general,
currency fluctuations, the impact of the global and European credit
crisis, and the ability to obtain or maintain patent or other
proprietary intellectual property protection. In light of these
risks and uncertainties, there can be no assurance that the
forward-looking statements made during this presentation will in
fact be realized. Valneva is providing the information in these
materials as of this press release, and disclaim any intention or
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise.
- 2020_06_18
Valneva_Bavarian_Commercial_Partnership_PR_EN_Final